Format:
Online-Ressource
ISSN:
2363-8915
Content:
Objectives: Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver. The aim of this study was the evaluation of the influence of CYP2D6*4 and CYP2D6*10 gene polymorphisms on the safety of medications containing 0.5% of timolol maleate as glaucoma treatment in patients with primary open-angle glaucoma (POAG). Methods: 105 patients with POAG were prescribed glaucoma medications, containing 0.5% timolol maleate. The safety of glaucoma treatment was determined by electrocardiography (ECG) (to assess heart rate (HR) and PQ interval) and blood pressure (BP) measurements. The real-time polymerase chain reaction method was used for the detection of single nucleotide polymorphisms (SNP). Results: The risk of adverse drug reactions was higher in patients with the CYP2D6*4 GA genotype compared with GG: mean HR change at 1 month (2.88 ± 4.68 and 6.44 ± 5.57, p〈0.001) and 6 months (5.14 ± 8.93 and 7.88 ± 5.65, p〈0.001), mean PQ interval change at 1 (0.01 ± 0.031 and 0.02 ± 0.022, p=0.003) and 6 months (0.01 ± 0.032 and 0.02 ± 0.024, p=0.003). The risk of adverse drug reactions was higher in patients with the CYP2D6*10 CT genotype compared with CC: mean HR change at 1 month (2.94 ± 4.65 and 6.34 ± 5.66, p〈0.001) and 6 months (5.20 ± 8.90 and 7.78 ± 5.75, p〈0.001), mean PQ interval change at 1 (0.01 ± 0.032 and 0.02 ± 0.021, p=0.014) and 6 months (0.01 ± 0.033 and 0.02 ± 0.022, p=0.014). Conclusions: CYP2D6*4 and CYP2D6*10 gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.
In:
volume:38
In:
number:2
In:
year:2022
In:
pages:143-148
In:
extent:06
In:
Drug metabolism and personalized therapy, Berlin ; Boston, Mass. : De Gruyter, 2015-, 38, Heft 2 (2022), 143-148 (gesamt 06), 2363-8915
Language:
English
DOI:
10.1515/dmpt-2022-0117
URN:
urn:nbn:de:101:1-2023060714093495799005
URL:
https://doi.org/10.1515/dmpt-2022-0117
URL:
https://nbn-resolving.org/urn:nbn:de:101:1-2023060714093495799005
URL:
https://d-nb.info/1292272104/34
Bookmarklink